
|Videos|April 16, 2019
Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer
Author(s)Suresh S. Ramalingam, MD
Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of brain metastases in <em>EGFR</em>-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.
Advertisement
Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of treating brain metastases inEGFR-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.
In the FLAURA trial, presented at the 2019 European Lung Cancer Congress, osimertinib showed intracranial responses.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tentative Approval to New Cabozantinib Capsule Formulation
2
FDA Clears Rituximab Biosimilar, Expanding Options for B-Cell Malignancies
3
In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade
4
Real-World Analysis Explores GLP-1 Use and Overall Survival
5










































